1 For most species, only a few 2D slices
were needed to accurately estimate Sm within 10% of the
2 al capacities, and low regeneration energies
are needed to achieve these separations efficiently at s
3 etween the dose of colistimethate that would
be needed to achieve a desired Css,avg and creatinine cl
4 mbining multiple sun protection measures may
be needed to achieve optimal protection.
5 ; however, at present additional scaffolding
is needed to achieve chromosome-level assemblies.
6 ns targeting multiple steps in the continuum
is needed to achieve the full beneficial impact of HIV t
7 this structure, it is unknown which factors
are needed to activate cumulus specific gene expression.
8 However, innovative approaches
are needed to address scale-up issues associated with th
9 detailed estimates of mortality differences
are needed to address this public health issue.
10 Future studies
are needed to address whether similar mechanisms contrib
11 rovision to cope with the increasing numbers
is needed to address avoidable vision loss.
12 And, what research
is needed to address gaps in our knowledge?
13 ves) will enable the robust stewardship that
is needed to address the current crisis of antibacterial
14 ncluding appropriate containment strategies,
is needed to address this situation.
15 evelopmental studies have contributed to and
are needed to advance clinical goals.
16 Standardized metrics for alert fatigue
is needed to advance the field.
17 that a given threshold of physical activity
is needed to age optimally and to maximise the 'healthsp
18 Further work
is needed to aid with the selection of patients most lik
19 Moreover, our data indicate that PI(4)P
is needed to anchor Arl8 (Arf-like GTPase 8) and its eff
20 Measures
are needed to ascertain the source of this compound to w
21 l new endpoints, as well as what new markers
are needed to assess the ability of HBV therapeutics to
22 Further studies
are needed to assess the comparative effectiveness of th
23 Larger scale clinical trials
are needed to assess the efficacy of gammaT supplements
24 More animal models
are needed to assess the functions of these genes in viv
25 Further studies
are needed to assess the potential roles of host protein
26 Prospective trials
are needed to assess the predictive value of the circula
27 Comparative evaluations
are needed to assess the suitability of near-road air po
28 iomarkers of progression in patients with RP
are needed to assess therapeutic outcomes.
29 However, longitudinal studies
are needed to assess this within abstaining smokers.
30 Further studies will
be needed to assess possible herd immunity effects with
31 Further research
is needed to assess generalizability and cost-effectiven
32 Further research
is needed to assess longer-term effectiveness, as well a
33 Further research
is needed to assess longer-term efficacy and adverse eff
34 Further study
is needed to assess safety and long-term clinical outcom
35 ells as well as their microenvironment which
is needed to assess the development of diseases.
36 edical properties; however, further research
is needed to assess the differences in their pharmacokin
37 Longer term follow-up
is needed to assess the durability of quality-of-life im
38 Critical appraisal of performance criteria
is needed to assess whether quality oversight is meeting
39 Surface anchoring groups
are needed to attach molecular units to photoanodes for
40 Better tools to identify indolent tumors
are needed to avoid overtreatment.
41 Further studies
are needed to better assess its safety and applicability
42 Longer-term studies
are needed to better assess the safety and clinical impa
43 is still largely overlooked and further data
are needed to better describe the group toxicity.
44 Further studies
are needed to better understand the functional underpinn
45 , but use of more precise diagnostic methods
is needed to better define epidemiology and underlying e
46 Research
is needed to better define the dose effect and its inter
47 Innovation in education and training
is needed to better prepare future nephrologists for the
48 tudying the role of regional hypermetabolism
is needed to better understand its interaction with the
49 nt wide-bandgap (WBG) perovskite solar cells
are needed to boost the efficiency of silicon solar cell
50 Strategies
are needed to care for and counsel patients with cancer
51 sive transfer of antisera and CD4(+) T cells
was needed to cause a significant reduction in NP coloni
52 s pathogenesis produced by different viruses
is needed to characterize virus and host-specific factor
53 Future studies
are needed to clarify the mechanism and to define the ro
54 Better tools
are needed to communicate the magnitude of risk to patie
55 hand-helded analyzers: conversion equations
are needed to compare the FENO values between these meth
56 Prospective studies
are needed to compare the value of CMR as compared to tr
57 Further studies
are needed to confirm a causal relationship.
58 Further studies
are needed to confirm and refine these recommendations.
59 Further studies
are needed to confirm the antitumour efficacy of the com
60 Additional imaging and pathologic studies
are needed to confirm these findings.
61 iseases; however, randomized clinical trials
are needed to confirm these findings.
62 Further studies
are needed to confirm these findings.
63 ients undergoing longer duration of sedation
are needed to confirm these observations.
64 Validation of this novel predictive score
is needed to confirm clinical utility.
65 Research
is needed to confirm possible interactions of arsenic me
66 sis difficult; therefore, laboratory testing
is needed to confirm the diagnosis.
67 ch using more robust epidemiological designs
is needed to confirm these findings.
68 ividual, population, and programmatic levels
are needed to confront the emerging drug-resistant HIV e
69 Future policy interventions
are needed to continue improvement in dietary quality an
70 the current-day magnitude of each component
is needed to create accurate projections of future relat
71 This
is needed to critically assess whether plasma technology
72 Prospective studies
are needed to define the impact of pretransplant sensiti
73 Larger prospective trials
are needed to define the optimal chemotherapy regimen.
74 ly as human ligands, although future studies
are needed to define their potential physiological role
75 clusion of controls for non-specific effects
is needed to define a range of additional, effective int
76 arious types of MDR-P. aeruginosa infections
is needed to define ceftolozane-tazobactam's place in th
77 Further work
is needed to define the role different IgG subtypes play
78 New strategies
are needed to design future therapies that target resist
79 Early and sustained efforts
are needed to detect infections and prevent or interrupt
80 .05; power = 80%) estimated that 2982 cases
were needed to detect a difference of at least 3%.
81 Future clinical trials focused on AYAs
are needed to determine effectiveness of therapies.
82 Further studies
are needed to determine how decreased sterol absorption
83 Further studies
are needed to determine if earlier AVR in these patients
84 More reliable methods
are needed to determine MGMT activity as DNA methylation
85 Further investigations
are needed to determine possible roles for PCNA and othe
86 Further studies
are needed to determine the life course progression of t
87 Studies
are needed to determine the mechanisms by which coffee m
88 inical trials investigating this combination
are needed to determine the optimal treatment strategy f
89 Therefore, studies
are needed to determine the role mGluR5 modulation might
90 ons of observational data, randomized trials
are needed to determine the role of MV-PCI in this setti
91 Further rigorous clinical studies
are needed to determine their efficacy and safety, as we
92 Further studies
are needed to determine whether specific subgroups of pe
93 ality trials and patient-based meta-analyses
are needed to determine whether subpopulations might ben
94 Further studies
are needed to determine whether these can be used as the
95 Studies
are needed to determine whether these features of PDACs
96 Larger trials will
be needed to determine short-term and long-term safety a
97 l longitudinal follow-up of eyes with drusen
is needed to determine if en face OCT imaging can replac
98 Further study of elamipretide
is needed to determine long-term safety and efficacy.
99 Longer follow-up
is needed to determine the impact of (18)F-fluciclovine
100 Further work
is needed to determine the implications of increased tha
101 BACKGROUND & AIMS: A system
is needed to determine the risk of patients with Barrett
102 More research
is needed to determine the validity of inflammation-corr
103 Long-term follow-up
is needed to determine the visual significance of these
104 ption of lipid-rich RUTFs, but more research
is needed to determine this.
105 l time and a fixed reference (e.g., GMT) [1]
were needed to determine longitude.
106 kidney-specific gene transfer in adult mice
are needed to develop new therapies for kidney disease.
107 r studies sharing the same imaging protocols
are needed to develop objective models for risk assessme
108 Further research
is needed to develop more effective pediatric fall preve
109 Research
is needed to develop safe and effective treatments, a pr
110 iscussed, noting areas in which further work
is needed to develop the next-generation POPs for practi
111 onates exposed in utero to Zika virus (ZIKV)
is needed to develop treatments.
112 re directions of research and reporting that
are needed to diminish it.
113 onstrate that exceptionally low temperatures
are needed to downregulate FvTFL1 and to make these plan
114 Future studies
are needed to elucidate the provenance and putative neur
115 Further studies
are needed to elucidate the source and epidemiology of P
116 More research
is needed to elucidate HOA risk factors, the mechanisms
117 Further research
is needed to elucidate the reasons underlying persistent
118 Although further research
is needed to elucidate the role of myelin in affecting e
119 referral systems from HEWs and health posts
are needed to enable consistent and timely access to Xpe
120 New global alliances
are needed to enable the combination of efforts and reso
121 essfully in rodents, but new infrastructures
are needed to enable these strategies in primates.
122 Novel strategies
are needed to enhance muscle repair and function and to
123 rative recovery programs for cancer patients
are needed to enhance survival after surgery.
124 traditional redox reactions, but strategies
are needed to enhance the performance of molecular catal
125 se.IMPORTANCE Development of novel adjuvants
is needed to enhance immunogenicity to provide better pr
126 Policy solutions
are needed to ensure availability of low-cost, essential
127 Customised service delivery
is needed to ensure parity for different geographic and
128 Antimicrobial stewardship
is needed to ensure prompt appropriate clinical action t
129 nts after congenital cardiac catheterization
is needed to equitably compare patient outcomes among di
130 Further follow-up studies
are needed to establish the long-term safety of these st
131 ctural properties within hearing organs that
are needed to establish tonotopic gradients.
132 ing skin-homing T-cell functional properties
are needed to establish whether CLA(+) memory subsets ca
133 Research
is needed to establish the cost-effectiveness of routine
134 tocin on neural circuits in the hypothalamus
is needed to establish the utility of targeting oxytocin
135 Relatively few sampling visits
were needed to estimate occupancy and detectability with
136 hat mimic in vivo host-pathogen interactions
are needed to evaluate candidate drugs that inhibit bact
137 However, more data
are needed to evaluate sufficient MPA sizes for protecti
138 Further studies
are needed to evaluate the clinical implications of our
139 Further studies
are needed to evaluate the mechanism of and opportunitie
140 iving (223)RaCl2 Further prospective studies
are needed to evaluate the potential of the BSI for resp
141 Carefully designed clinical trials
are needed to evaluate these potential applications, and
142 However, further studies
are needed to evaluate whether the control of metabolic
143 Future studies
are needed to evaluate whether this uncertainty also inf
144 Longer follow up would
be needed to evaluate the potential use of the visual st
145 Post-market surveillance
is needed to evaluate the real-world clinical effectiven
146 ions are defined biochemically, but a method
is needed to evaluate them quantitatively within morphol
147 Therefore, a rapid preclinical approach
is needed to evaluate whether simultaneous or sequential
148 Further research
is needed to examine its role in patients with evidence
149 R-pMHC interactions with Kds of </=15 microM
were needed to exclude CD45.
150 Further studies
are needed to explain the residual part of the spatial v
151 implies little unmeasured confounding would
be needed to explain away an effect estimate.
152 at considerable unmeasured confounding would
be needed to explain away an effect estimate.
153 arity, and suggest that a more complex model
is needed to explain the effects of PID.
154 neering the variants in model organisms will
be needed to explore whether human variants in ANGPTL6 a
155 Further research
is needed to explore optimal donor selection, FT prepara
156 dent replication in population-based studies
is needed to extend these findings.
157 ng regulatory networks (RN) and genomic data
are needed to extract biological information for a bette
158 eful, nuanced models of language change will
be needed to extract deeper signal from the noise of par
159 -Cas9 tools for site-specific genome editing
are needed to facilitate further improvements in the BIC
160 ons and policy and enabling environment that
are needed to facilitate widespread adaptation may be ve
161 better understanding of the pathology of CP
is needed to facilitate improved diagnosis and treatment
162 New analytical tools
are needed to fill the void for detection and visualizat
163 Standardised assessments in diverse settings
are needed to fully determine the effect of intervention
164 Further studies
are needed to fully explore the complement of diversity
165 sing on multiple aspects of disease activity
are needed to fully understand the natural history of Eo
166 the wide-scale use of neonics, more studies
are needed to fully understand their effects on human he
167 the age-data indicate decades or longer may
be needed to fully assess the effects of potential subsu
168 Larger studies in AAs will
be needed to fully elucidate the underlying determinants
169 her study using a different luminal promoter
is needed to fully support this conclusion.
170 ified research gaps, but specific objectives
are needed to further behavioral intervention research.
171 director attitudes, although larger studies
are needed to further define program factors affecting a
172 in limited, and future comprehensive studies
are needed to further elucidate this disease, which coul
173 ditional high-quality interventional studies
are needed to further evaluate the effectiveness of pati
174 psychological, and clinical assessments also
are needed to further evaluate the model proposed.
175 Intervention trials
are needed to further examine the effect of flavonoid-ri
176 tional patients and longer follow-up periods
are needed to further explore the utility of rituximab i
177 s and processes behind observed improvements
is needed to further reduce the burden of injury in Cana
178 behavior change; however, systematic studies
are needed to identify and validate targets and to disco
179 Better tools
are needed to identify patients at high risk of developi
180 New methods
are needed to identify promising drug candidates earlier
181 Reliable response biomarkers
are needed to identify responders, and conventional imag
182 Additional studies
are needed to identify sources of variability in express
183 well-designed prospective multicenter trials
are needed to identify the most effective new agents and
184 Additional studies
are needed to identify the optimal DAA regimen for kidne
185 Future work
is needed to identify and evaluate innovative culture ch
186 More research
is needed to identify barriers to uptake of CBE at home
187 More research
is needed to identify effects of genetic variation on di
188 As such, more research
is needed to identify level and type (positive/negative
189 ical approach and conclude that further work
is needed to identify stable and reliable measures of fi
190 Further research
is needed to identify strategies to improve the quality
191 Further study
is needed to identify the critical practice elements tha
192 r, three anaesthetic-sensitive rho1 subunits
are needed to impart full efficacy to the partial GABA a
193 Integrated strategies
are needed to improve access to and uptake of HIV testin
194 rategies targeting humoral immune reactivity
are needed to improve long-term intestinal graft outcome
195 Continued efforts
are needed to improve patient selection and procedural/p
196 ces regarding risk of SSI versus risk of AKI
is needed to improve clinical decision-making.
197 h type 2 diabetes when pharmacologic therapy
is needed to improve glycemic control.
198 n of biliary complications, especially ITBL,
is needed to improve the outcomes for DCD grafts.
199 dardized protocols for sampling and analysis
is needed to improve the reproducibility and comparabili
200 of clinical subtypes, and further refinement
is needed to improve treatment outcomes.
201 Interventions
are needed to increase high-intensity statin use and adh
202 Targeted efforts
are needed to increase the number of medical students ch
203 els that can regulate cytoplasmic Ca(2+) and
are needed to induce the expression of a BELL1-like tran
204 Rigid matrix
is needed to induce rapid nuclear accumulation of the RA
205 complex's second reduction, a third electron
is needed to induce the second proton addition from the
206 studies of morphologically different species
are needed to infer the principles of organogenesis.
207 More data
are needed to inform next steps in the responsible stewa
208 th human immunodeficiency virus (HIV) (WHIV)
are needed to inform prevention programs for this popula
209 context of the full continuum of iron status
is needed to inform approaches to the balancing of benef
210 ic factors underlying neonicotinoid residues
is needed to inform evidence-based policy.
211 Research
is needed to inform firm recommendations on how to prote
212 More research
is needed to inform our knowledge of the role of insuran
213 the neural bases of rehabilitation efficacy
is needed to inform therapeutic efforts to improve it.
214 ation of FX by SR-AI, and the presence of FX
is needed to interfere with internalization of PTX2.
215 While further studies
are needed to investigate abilities of the PCs of only I
216 Studies
are needed to investigate associations between risk fact
217 New animal models
are needed to investigate CYP3A functions, especially fo
218 Future trials
are needed to investigate further the use of DSM265 for
219 Future studies
are needed to investigate the role of baseline nutrition
220 Further studies
are needed to investigate the role of specific genes inv
221 More studies
are needed to investigate the use of bone turnover marke
222 Further research
is needed to investigate how findings from this group of
223 Further research
is needed to investigate the association between these s
224 A prospective study
is needed to investigate the effectiveness of IB in Japa
225 Research
is needed to investigate the potential of DNA-(de)methyl
226 gation strategies, and examples of efficacy,
are needed to justify producer adoption.
227 ivers cells and biologics to IVD injury site
is needed to limit the progression of disc degeneration
228 Prevention and management strategies
are needed to maintain high quality of care for all pati
229 ctive, accessible biopsychosocial treatments
are needed to manage chronic knee pain on a population l
230 rventions to decrease these adverse outcomes
are needed to maximize the overall effectiveness of supp
231 sistently violate expectations, new learning
is needed to maximize rewards.
232 nent is the Rubisco-containing pyrenoid that
is needed to minimise CO2 retro-diffusion for CCM operat
233 smission and missed prevention opportunities
are needed to monitor progress toward elimination of mot
234 ion of the PSF framework to the phyllosphere
is needed to more fully elucidate plant-microbiota inter
235 lication of these findings in larger samples
is needed to more precisely estimate variance explained
236 In-depth conceptual analyses
are needed to move research in religious involvement and
237 New studies
are needed to optimize and standardize extracorporeal ci
238 on the utility, accuracy, and safety of PLB
are needed to optimize its use.
239 interventions to attenuate inflammation may
be needed to optimize clinical outcomes in persons with
240 More work
is needed to optimize its dosing to minimize adverse eve
241 Large collaborations and novel approaches
are needed to overcome the genetic heterogeneity of panc
242 and elucidation of its underlying mechanisms
are needed to place these results in a clinical perspect
243 ions of future mortality and life expectancy
are needed to plan for health and social services and pe
244 alpha (called 'IL-6 cluster signaling' here)
was needed to prevent premature induction of interferon-
245 of the long-term influence of these factors
is needed to prioritise public health investments to opt
246 rt, cells of different material compositions
are needed to produce devices of tailor made characteris
247 Clinical trials
are needed to provide treatment guidance for the group w
248 Therefore, highly sensitive methods
are needed to quantify BPA in various matrices including
249 ress scenario), whereas US$371 billion would
be needed to reach health system targets in the ambitiou
250 collaboration with the affected populations
are needed to realise the benefits of existing intervent
251 and rehospitalization remain unexplored and
are needed to reduce readmissions.
252 Measures
are needed to reduce risk behaviors and increase monitor
253 es and that interdisciplinary collaborations
are needed to reduce the harms of gambling.
254 Significant population health interventions
are needed to reduce the HF hospitalization burden among
255 New approaches
are needed to reduce the industry's footprint.
256 ve physician-patient communication about CPM
is needed to reduce potential overtreatment.
257 strengths of the intermolecular interactions
are needed to regulate the formation of different domain
258 Processing of the R-loops
is needed to remove RNA allowing activation-induced (cyt
259 Therapies that stimulate axon growth
are needed to repair CNS damage.
260 Further study
is needed to replicate these findings and identify poten
261 Further research
is needed to replicate these findings, determine their c
262 As a result, substantial lead time
was needed to resolve procurement and regulatory issues
263 Interventions
are needed to safeguard the health of women after fistul
264 w concepts and strategies of material design
are needed to smooth each pivotal step.
265 of the 3-dimensional organization of the IC
is needed to specify how the single tonotopic representa
266 asurement, and confirm that lambda < 1/(n-1)
is needed to sufficiently suppress multispin effects (wi
267 hes that utilize properties intrinsic to DNA
are needed to supplement training based methods and to e
268 solidation (15-19 years), when new responses
are needed to support brain maturation, intense social e
269 xperimental systems for new-onset/chronic AD
are needed to support rapid therapeutic development, par
270 dent of the nucleotide substitution analyses
is needed to support a primary role of genetic drift dri
271 Shared decision making
is needed to support decisions about breast reconstructi
272 rge equilibration method (PQEq) method might
be needed to take the effects of Efields into considerat
273 inevitable, and novel therapeutic approaches
are needed to target dormant tumors.
274 Prospective randomized clinical trials
are needed to test ICD efficacy in patients with an EF >
275 arch with a robust dietary intake assessment
is needed to test this hypothesis.
276 A prospective registry
is needed to track the long-term risks of systemic agent
277 Novel therapeutic interventions
are needed to treat SZ and DBS is emerging as a potentia
278 Larger studies
are needed to understand the clinical implications of th
279 More data
are needed to understand the disconnect between efficacy
280 Further studies
are needed to understand the effects of administration o
281 humans and some primates, new animal models
are needed to understand the function of APOL1 in vivo W
282 Spectroscopic approaches
are needed to understand the mechanisms by which TRPV1 t
283 igh-resolution structures of metalloamyloids
are needed to understand the molecular bases of metal-am
284 Further studies
are needed to understand the sociodemographic and health
285 More science
is needed to understand how the brain is affected by ear
286 Further research
is needed to understand how these noncardiac complicatio
287 Further research
is needed to understand possible modifiers of these asso
288 of the effect of the environment on the host
is needed to understand the disease.
289 More research
is needed to understand the effectiveness of screening a
290 g beetles and P. carabi mites, but more work
is needed to understand the functional significance and
291 in isolated case reports; thus, further work
is needed to understand the impact of mutation chronolog
292 Further research
is needed to understand the mechanisms influencing micro
293 seen in white populations, but further study
is needed to understand whether African American individ
294 More work
is needed to understand why there was no clinical benefi
295 otent stem (iPS) cell-derived neuronal cells
are needed to validate our preliminary findings especial
296 studies with multiple postoperative measures
are needed to validate the effect of these potential bio
297 Additional larger studies
are needed to validate the effects of prolonged anakinra
298 Further studies
are needed to validate this finding in Ugandan and other
299 Future investigations will
be needed to validate these therapeutic techniques for p
300 n the treatment of IBD, but further research
is needed to validate these approaches.